Abstract
Pharmacokinetics is the study of the fate of xenobiotics in a living organism. Physiologically based pharmacokinetic (PBPK) models provide realistic descriptions of xenobiotics’ absorption, distribution, metabolism, and excretion processes. They model the body as a set of homogeneous compartments representing organs, and their parameters refer to anatomical, physiological, biochemical, and physicochemical entities. They offer a quantitative mechanistic framework to understand and simulate the time-course of the concentration of a substance in various organs and body fluids. These models are well suited for performing extrapolations inherent to toxicology and pharmacology (e.g., between species or doses) and for integrating data obtained from various sources (e.g., in vitro or in vivo experiments, structure–activity models). In this chapter, we describe the practical development and basic use of a PBPK model from model building to model simulations, through implementation with an easily accessible free software.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haggard HW (1924) The absorption, distribution, and elimination of ethyl ether. I. The amount of ether absorbed in relation to the concentration inhaled and its fate in the body. J Biol Chem 59:737–751
Haggard HW (1924) The absorption, distribution, and elimination of ethyl ether. II. Analysis of the mechanism of absorption and elimination of such a gas or vapor as ethyl ether. J Biol Chem 59:753–770
Haggard HW (1924) The absorption, distribution, and elimination of ethyl ether. III. The relation of the concentration of ether, or any similar volatile substance, in the central nervous system to the concentration in the arterial blood, and the buffer action of the body. J Biol Chem 59:771–781
Haggard HW (1924) The absorption, distribution, and elimination of ethyl ether. IV. The anesthetic tension of ether and the physiological response to various concentrations. J Biol Chem 59:783–793
Haggard HW (1924) The absorption, distribution, and elimination of ethyl ether. V. The importance of the volume of breathing during the induction and termination of ether anesthesia. J Biol Chem 59:795–802
Teorell T (1937) Kinetics of distribution of substances administered to the body. Arch Int Pharmacodyn Ther 57:205–240
Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
Bischoff KB, Dedrick RL, Zaharko DS et al (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128–1133
Dedrick RL, Forrester DD, Cannon JN et al (1973) Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol 22:2405–2417
Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103–1127
Droz PO, Guillemin MP (1983) Human styrene exposure—V. Development of a model for biological monitoring. Int Arch Occup Environ Health 53:19–36
Lutz RJ, Dedrick RL, Tuey D et al (1984) Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. Drug Metab Dispos 12:527–535
Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45–73
Nestorov I, Aarons L, Rowland M (1998) Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J Pharmacokinet Biopharm 26:521–545
Peyret T, Poulin P, Krishnan K (2010) A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 249:197–207
Jones HM, Parrott N, Jorga K et al (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–542
Beaudouin R, Micallef S, Brochot C (2010) A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan. Regul Toxicol Pharmacol 57:103–116
Clewell HJ III, Gentry PR, Covington TR et al (2004) Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79:381–393
United States Environmental Protection Agency (US EPA) (2006) Approaches for the application of Physiologically Based Pharmacokinetic (PBPK) models and supporting data in risk assessment (final report). United States Environmental Protection Agency, Washington, DC
International Programme on Chemical Safety (IPCS) (2010) Characterization and application of physiologically based pharmacokinetic models in risk assessment, World Health Organization. International Programme on Chemical Safety, Geneva
Peters SA (2011) Physiologically Based Pharmacokinetic (pbpk) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. Wiley, Hoboken, NJ
Andersen ME (1995) What do we mean by … dose? Inhal Toxicol 7:909–915
Clewell HJ, Tan YM, Campbell JL et al (2008) Quantitative interpretation of human biomonitoring data. Toxicol Appl Pharmacol 231:122–133
Ulaszewska MM, Ciffroy P, Tahraoui F et al (2012) Interpreting PCB levels in breast milk using a physiologically based pharmacokinetic model to reconstruct the dynamic exposure of Italian women. J Expo Sci Environ Epidemiol 22:601–609
Zeman FA, Boudet C, Tack K et al (2013) Exposure assessment of phthalates in French pregnant women: results of the ELFE pilot study. Int J Hyg Environ Health 216:271–279
Loizou G, Spendiff M, Barton HA et al (2008) Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol 50:400–411
Barton HA, Chiu WA, Setzer W et al (2007) Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation. Toxicol Sci 99:395–402
Andersen ME (1995) Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Lett 79:35–44
Clewell RA, Clewell HJ (2008) Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol 50:129–143
Campbell JL Jr, Clewell RA, Gentry PR et al (2012) Physiologically based pharmacokinetic/toxicokinetic modeling. In: Reisfeld B, Mayeno AN (eds) Computational toxicology, Methods in molecular biology series. Humana, New York, pp 439–499
Thompson MD, Beard DA (2011) Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport. J Pharmacokinet Pharmacodyn 38:405–421
International Commission on Radiological Protection (ICRP) (1975) Report of the Task Group on Reference Man—a report prepared by a Task Group of Committee 2 of the International Commission on Radiological Protection. Pergamon, Oxford
International Commission on Radiological Protection (ICRP) (2002) Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89. Ann ICRP 32(3–4):5–265
Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095
Brown RP, Delp MD, Lindstedt ST et al (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 14:407–484
Young JF, Branham WS, Sheenan DM et al (1997) Physiological “constants” for PBPK models for pregnancy. J Toxicol Environ Health 52:385–401
Ekins S, Waller CL, Swaan PW et al (2000) Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251–272
Poulin P, Haddad S (2012) Advancing prediction of tissue distribution and volume of distribution of highly lipophilic compounds from a simplified tissue-composition-based model as a mechanistic animal alternative method. J Pharm Sci 101:2250–2261
Butina D, Segall MD, Frankcombe K (2002) Predicting ADME properties in silico: methods and models. Drug Discov Today 7:S83–S88
Buch I, Giorgino T, De Fabritiis G (2011) Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A 108(25):10184–10189
Fiserova-Bergerova V, Diaz ML (1986) Determination and prediction of tissue-gas partition coefficients. Int Arch Occup Environ Health 58:75–87
Gargas ML, Seybold PG, Andersen ME (1988) Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. Toxicol Lett 43:235–256
Poulin P, Theil FP (2000) A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16–35
Poulin P, Ekins S, Theil FP (2011) A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 250:194–212
Adler S, Basketter D, Creton S et al (2011) Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010. Arch Toxicol 85:367–485
Bal-Price A, Jennings P (eds) (2014) In vitro toxicology systems. Humana, New York
Bois FY, Jamei M (2012) Population-based pharmacokinetic modeling and simulation. In: Lyubimov AV (ed) Encyclopedia of drug metabolism and interactions. Wiley, Hoboken, pp 1–27
Yuh L, Beal S, Davidian M et al (1994) Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics 50:566–575
Bernillon P, Bois FY (2000) Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 108(Suppl 5):883–893
Gelman A, Bois FY, Jiang J (1996) Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 91:1400–1412
Bois FY, Jamei M, Clewell HJ (2010) PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:256–267
R Development Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Bois FY (2009) GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. Bioinformatics 25:1453–1454
Anonymous. GNU MCSim. http://www.gnu.org/software/mcsim/
Anonymous. GNU Octave. http://www.gnu.org/software/octave/
Anonymous Scilab. http://www.scilab.org/
Anonymous. MATLAB and Simulink for technical computing—MathWorks. http://mathworks.com/
Anonymous. Wolfram mathematica: definitive system for modern technical computing. http://www.wolfram.com/mathematica/
Anonymous. Bayer technology services: PK-Sim®. http://www.systems-biology.com/products/pk-sim.html
Anonymous. Simcyp—population based pharmacokinetic modelling and simulation. http://www.simcyp.com/
Anonymous. Simulations Plus, Inc|Modeling & Simulation Software|Consulting Services for Pharmaceutical Research. http://www.simulations-plus.com/
Anonymous. MERLIN-Expo|Exposure Assessment Software. http://merlin-expo.4funproject.eu/
Bois FY (2009) Physiologically-based modelling and prediction of drug interactions. Basic Clin Pharmacol Toxicol 106:154–161
United States Environmental Protection Agency (US EPA) (2002) Health Assessment of 1,3-Butadiene. United States Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington Office, Washington, DC
Kirman CR, Albertini RJ, Sweeney LM et al (2010) 1,3-Butadiene: I. Review of metabolism and the implications to human health risk assessment. Crit Rev Toxicol 40:1–11
Bois FY, Smith T, Gelman A et al (1999) Optimal design for a study of butadiene toxicokinetics in humans. Toxicol Sci 49:213–224
Mezzetti M, Ibrahim JG, Bois FY et al (2003) A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. J R Stat Soc Ser C 52:291–305
Bois F (2012) Bayesian inference. In: Reisfeld B, Mayeno AN (eds) Computational toxicology, vol II. Humana, New York, pp 597–636
Deurenberg P, Weststrate JA, Seidell JC (1991) Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 65:105–141
Byrne GD, Hindmarsh AC (1987) Stiff ODE solvers: a review of current and coming attractions. J Comput Phys 70:1–62
Caldwell JC, Evans MV, Krishnan K (2012) Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms. J Toxicol 2012:852384
Zhao P, Zhang L, Grillo JA et al (2011) Applications of Physiologically Based Pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259–267
Zhao P, Rowland M, Huang S-M (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17–20
Rostami-Hodjegan A, Tamai I, Pang KS (2012) Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! Biopharm Drug Dispos 33:47–50
Geenen S, Yates JW, Kenna JG et al (2013) Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Integr Biol 5:877–888
Acknowledgment
This work was partly supported by the European Commission, 7th FP project 4-FUN (grant agreement 308440) and the French Ministry for the Environment (Programme 190 toxicologie).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
R script for the butadiene PBPK model:
#=================================================================
# Butadiene human PBPK model
# Define and initialize the state variables
y = c("Q_fat" = 0, # Quantity of butadiene in fat (mg)
"Q_wp" = 0, # ~ in well-perfused (mg)
"Q_pp" = 0, # ~ in poorly-perfused (mg)
"Q_met" = 0) # ~ metabolized (mg)
# Define the model parameters
# Units:
# Volumes: liter
# Time: minute
# Flows: liter / minute
parameters = c(
"BDM" = 73, # Body mass (kg)
"Height" = 1.6, # Body height (m)
"Age" = 40, # in years
"Sex" = 1, # code 1 is male, 2 is female
"Flow_pul" = 5, # Pulmonary ventilation rate (L/min)
"Pct_Deadspace" = 0.7, # Fraction of pulmonary deadspace
"Vent_Perf" = 1.14, # Ventilation over perfusion ratio
"Pct_LBDM_wp" = 0.2, # wp tissue as fraction of lean mass
"Pct_Flow_fat" = 0.1, # Fraction of cardiac output to fat
"Pct_Flow_pp" = 0.35, # ~ to pp
"PC_art" = 2, # Blood/air partition coefficient
"PC_fat" = 22, # Fat/blood ~
"PC_wp" = 0.8, # wp/blood ~
"PC_pp" = 0.8, # pp/blood ~
"Kmetwp" = 0.25) # Rate constant for metabolism (1/min)
# The input air concentration (in parts per million) can vary with time
C_inh = approxfun(x = c(0,120), y = c(10,0), method="constant", f=0, rule=2)
# Check the input concentration profile just defined
plot(C_inh(1:300), xlab = "Time (min)",
ylab = "Butadiene air concentration (ppm)", type = "l")
# Define the model equations
bd.model = function(t, y, parameters) {
with (as.list(y), {
with (as.list(parameters), {
# Define some useful constants
MW_bu = 54.0914 # butadiene molecular weight (in grams)
ppm_per_mM = 24450 # ppm to mM under normal conditions
# Conversions from/to ppm
ppm_per_mg_per_l = ppm_per_mM / MW_bu
mg_per_l_per_ppm = 1 / ppm_per_mg_per_l
# Calculate Flow_alv from total pulmonary flow
Flow_alv = Flow_pul * (1 - Pct_Deadspace)
# Calculate total blood flow from Flow_alv and the V/P ratio
Flow_tot = Flow_alv / Vent_Perf
# Calculate fraction of body fat
Pct_BDM_fat = (1.2 * BDM / (Height * Height) - 10.8 *(2 - Sex) +
0.23 * Age - 5.4) * 0.01
# Actual volumes, 10% of body mass (bones…) get no butadiene
Eff_V_fat = Pct_BDM_fat * BDM
Eff_V_wp = Pct_LBDM_wp * BDM * (1 - Pct_BDM_fat)
Eff_V_pp = 0.9 * BDM - Eff_V_fat - Eff_V_wp
# Calculate actual blood flows from total flow and percent flows
Flow_fat = Pct_Flow_fat * Flow_tot
Flow_pp = Pct_Flow_pp * Flow_tot
Flow_wp = Flow_tot * (1 - Pct_Flow_pp - Pct_Flow_fat)
# Calculate the concentrations
C_fat = Q_fat / Eff_V_fat
C_wp = Q_wp / Eff_V_wp
C_pp = Q_pp / Eff_V_pp
# Venous blood concentrations at the organ exit
Cout_fat = C_fat / PC_fat
Cout_wp = C_wp / PC_wp
Cout_pp = C_pp / PC_pp
# Sum of Flow * Concentration for all compartments
dQ_ven = Flow_fat * Cout_fat + Flow_wp * Cout_wp + Flow_pp * Cout_pp
C_inh.current = C_inh(t) # to avoid calling C_inh() twice
# Arterial blood concentration
# Convert input given in ppm to mg/l to match other units
C_art = (Flow_alv * C_inh.current * mg_per_l_per_ppm + dQ_ven) /
(Flow_tot + Flow_alv / PC_art)
# Venous blood concentration (mg/L)
C_ven = dQ_ven / Flow_tot
# Alveolar air concentration (mg/L)
C_alv = C_art / PC_art
# Exhaled air concentration (ppm!)
if (C_alv <= 0) {
C_exh = 10E-30 # avoid round off errors
} else {
C_exh = (1 - Pct_Deadspace) * C_alv * ppm_per_mg_per_l +
Pct_Deadspace * C_inh.current
}
# Quantity metabolized in liver (included in well-perfused)
dQmet_wp = Kmetwp * Q_wp
# Differentials for quantities
dQ_fat = Flow_fat * (C_art - Cout_fat)
dQ_wp = Flow_wp * (C_art - Cout_wp) - dQmet_wp
dQ_pp = Flow_pp * (C_art - Cout_pp)
dQ_met = dQmet_wp
# The function bd.model must return at least the derivatives
list(c(dQ_fat, dQ_wp, dQ_pp, dQ_met), # derivatives
c("C_ven" = C_ven, "C_art" = C_art)) # extra outputs
}) # end with parameters
}) # end with y
} # end bd.model
# Define the computation output times
times = seq(from=0, to=1440, by=10)
# Call the ODE solver
library(deSolve)
results = ode(times = times, func = bd.model, y = y, parms = parameters)
# results is basically a table
results
# Plot the results of the simulation
plot(results)
# End
# End Simple Simulation.
#=================================================================
#=================================================================
# Monte Carlo simulations
# We assume that a simple simulation has already been run, so that
# y, parameters, C_inh, and bd.model have all been defined and that
# deSolve has been loaded.
for (iteration in 1:1000) { # 1000 Monte Carlo simulations…
# Sample randomly some parameters
parameters["BDM"] = rnorm(1, 73, 7.3)
parameters["Flow_pul"] = rnorm(1, 5, 0.5)
parameters["PC_art"] = rnorm(1, 2, 0.2)
parameters["Kmetwp"] = rnorm(1, 0.25, 0.025)
# Reduce output times eventually. We only care about time 1440,
# but time zero still needs to be specified
times = c(0, 1440)
# Integrate
tmp = ode(times = times, func = bd.model, y = y, parms = parameters)
if (iteration == 1) { # initialize
results = tmp[2,-1]
sampled.parms = c(parameters["BDM"], parameters["Flow_pul"],
parameters["PC_art"], parameters["Kmetwp"])
} else { # accumulate
results = rbind(results, tmp[2,-1])
sampled.parms = rbind(sampled.parms,
c(parameters["BDM"], parameters["Flow_pul"],
parameters["PC_art"], parameters["Kmetwp"]))
}
} # end Monte Carlo loop
# Save the results, specially if they took a long time to compute
save(sampled.parms, results, file="MTC.dat.xz", compress = "xz")
# use load(file="MTC.dat.xz") to read them back in
# Plot the results
hist(sampled.parms[,1])
hist(results[,1])
plot(sampled.parms[,1], results[,1])
# End Monte Carlo Simulations.
#=================================================================
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Bois, F.Y., Brochot, C. (2016). Modeling Pharmacokinetics. In: Benfenati, E. (eds) In Silico Methods for Predicting Drug Toxicity. Methods in Molecular Biology, vol 1425. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3609-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3609-0_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3607-6
Online ISBN: 978-1-4939-3609-0
eBook Packages: Springer Protocols